Rapt Therapeutics Inc
NASDAQ:RAPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Rapt Therapeutics Inc
Total Assets
Rapt Therapeutics Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rapt Therapeutics Inc
NASDAQ:RAPT
|
Total Assets
$165.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$134B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
Rapt Therapeutics Inc
Glance View
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. FLX475 is in Phase I/II clinical trials. Its lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues.
See Also
What is Rapt Therapeutics Inc's Total Assets?
Total Assets
165.7m
USD
Based on the financial report for Sep 30, 2025, Rapt Therapeutics Inc's Total Assets amounts to 165.7m USD.
What is Rapt Therapeutics Inc's Total Assets growth rate?
Total Assets CAGR 5Y
5%
Over the last year, the Total Assets growth was 53%. The average annual Total Assets growth rates for Rapt Therapeutics Inc have been -8% over the past three years , 5% over the past five years .
